Loading...
Loading...
In a report published Tuesday, Morgan Stanley analyst James Francescone reiterated an Equal-Weight rating on
HaemoneticsHAE.
In the report, Morgan Stanley noted, “Weak results and guidance have become less surprising over the past several quarters. In the face of changing markets, management remains committed to same strategy that has failed to drive traction for several years. Our base case declines to $33 from $40 on large EPS revisions; we remain EW.”
Haemonetics closed on Monday at $31.19.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in